Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Identifieur interne : 002399 ( Main/Exploration ); précédent : 002398; suivant : 002400Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Auteurs : Keunchil Park [Corée du Sud] ; Eng-Huat Tan [Singapour] ; Ken O'Byrne [Australie] ; Li Zhang [République populaire de Chine] ; Michael Boyer [Australie] ; Tony Mok [Hong Kong] ; Vera Hirsh [Canada] ; James Chih-Hsin Yang [Taïwan] ; Ki Hyeong Lee [Corée du Sud] ; Shun Lu [République populaire de Chine] ; Yuankai Shi [République populaire de Chine] ; Sang-We Kim [Corée du Sud] ; Janessa Laskin [Canada] ; Dong-Wan Kim [Corée du Sud] ; Catherine Dubos Arvis [France] ; Karl Kölbeck [Suède] ; Scott A. Laurie [Canada] ; Chun-Ming Tsai [Taïwan] ; Mehdi Shahidi [Royaume-Uni] ; Miyoung Kim [Allemagne] ; Dan Massey [Royaume-Uni] ; Victoria Zazulina [Royaume-Uni] ; Luis Paz-AresSource :
- The Lancet. Oncology [ 1474-5488 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (génétique), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Effets secondaires indésirables des médicaments (), Effets secondaires indésirables des médicaments (génétique), Effets secondaires indésirables des médicaments (physiopathologie), Estimation de Kaplan-Meier, Femelle, Humains, Inhibiteurs de protéines kinases (administration et posologie), Inhibiteurs de protéines kinases (effets indésirables), Mutation, Mâle, Quinazolines (administration et posologie), Quinazolines (effets indésirables), Récepteur du facteur de croissance épidermique (génétique), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
- MESH :
- administration et posologie : Inhibiteurs de protéines kinases, Quinazolines.
- anatomopathologie : Carcinome pulmonaire non à petites cellules.
- effets indésirables : Inhibiteurs de protéines kinases, Quinazolines.
- génétique : Carcinome pulmonaire non à petites cellules, Effets secondaires indésirables des médicaments, Récepteur du facteur de croissance épidermique.
- physiopathologie : Effets secondaires indésirables des médicaments.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules.
- Adulte, Adulte d'âge moyen, Effets secondaires indésirables des médicaments, Estimation de Kaplan-Meier, Femelle, Humains, Mutation, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (genetics), Carcinoma, Non-Small-Cell Lung (pathology), Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions (classification), Drug-Related Side Effects and Adverse Reactions (genetics), Drug-Related Side Effects and Adverse Reactions (physiopathology), Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mutation, Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (adverse effects), Quinazolines (administration & dosage), Quinazolines (adverse effects), Receptor, Epidermal Growth Factor (genetics).
- MESH :
- chemical , administration & dosage : Protein Kinase Inhibitors, Quinazolines.
- chemical , adverse effects : Protein Kinase Inhibitors, Quinazolines.
- classification : Drug-Related Side Effects and Adverse Reactions.
- drug therapy : Carcinoma, Non-Small-Cell Lung.
- genetics : Carcinoma, Non-Small-Cell Lung, Drug-Related Side Effects and Adverse Reactions, Receptor, Epidermal Growth Factor.
- pathology : Carcinoma, Non-Small-Cell Lung.
- physiopathology : Drug-Related Side Effects and Adverse Reactions.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Mutation.
Abstract
The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.
DOI: 10.1016/S1470-2045(16)30033-X
PubMed: 27083334
Affiliations:
- Allemagne, Australie, Canada, Corée du Sud, France, Hong Kong, Royaume-Uni, République populaire de Chine, Singapour, Suède, Taïwan
- Basse-Normandie, Guangdong, Québec, Région Normandie, Région capitale de Séoul, Svealand
- Caen, Jiangmen, Montréal, Pékin, Stockholm, Séoul
- Université McGill
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001E66
- to stream PubMed, to step Curation: 001E42
- to stream PubMed, to step Checkpoint: 001E42
- to stream Ncbi, to step Merge: 003419
- to stream Ncbi, to step Curation: 003419
- to stream Ncbi, to step Checkpoint: 003419
- to stream Main, to step Merge: 002398
- to stream Main, to step Curation: 002399
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.</title><author><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name><affiliation wicri:level="3"><nlm:affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: kpark@skku.edu.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Tan, Eng Huat" sort="Tan, Eng Huat" uniqKey="Tan E" first="Eng-Huat" last="Tan">Eng-Huat Tan</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Centre, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>National Cancer Centre, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="O Byrne, Ken" sort="O Byrne, Ken" uniqKey="O Byrne K" first="Ken" last="O'Byrne">Ken O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Boyer, Michael" sort="Boyer, Michael" uniqKey="Boyer M" first="Michael" last="Boyer">Michael Boyer</name><affiliation wicri:level="1"><nlm:affiliation>Chris O'Brien Lifehouse, Camperdown, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Chris O'Brien Lifehouse, Camperdown, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong Sha Tin, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong Sha Tin</wicri:regionArea><wicri:noRegion>The Chinese University of Hong Kong Sha Tin</wicri:noRegion></affiliation></author><author><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name><affiliation wicri:level="4"><nlm:affiliation>McGill University, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>McGill University, Montreal, QC</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Yang, James Chih Hsin" sort="Yang, James Chih Hsin" uniqKey="Yang J" first="James Chih-Hsin" last="Yang">James Chih-Hsin Yang</name><affiliation wicri:level="1"><nlm:affiliation>National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Ki Hyeong" sort="Lee, Ki Hyeong" uniqKey="Lee K" first="Ki Hyeong" last="Lee">Ki Hyeong Lee</name><affiliation wicri:level="1"><nlm:affiliation>Chungbuk National University Hospital, Cheongju, Chungbuk, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Chungbuk National University Hospital, Cheongju, Chungbuk</wicri:regionArea><wicri:noRegion>Chungbuk</wicri:noRegion></affiliation></author><author><name sortKey="Lu, Shun" sort="Lu, Shun" uniqKey="Lu S" first="Shun" last="Lu">Shun Lu</name><affiliation wicri:level="1"><nlm:affiliation>Shanghai Chest Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai Chest Hospital, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Shi, Yuankai" sort="Shi, Yuankai" uniqKey="Shi Y" first="Yuankai" last="Shi">Yuankai Shi</name><affiliation wicri:level="3"><nlm:affiliation>Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Kim, Sang We" sort="Kim, Sang We" uniqKey="Kim S" first="Sang-We" last="Kim">Sang-We Kim</name><affiliation wicri:level="3"><nlm:affiliation>Asan Medical Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Asan Medical Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Laskin, Janessa" sort="Laskin, Janessa" uniqKey="Laskin J" first="Janessa" last="Laskin">Janessa Laskin</name><affiliation wicri:level="1"><nlm:affiliation>BC CancerAgency, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>BC CancerAgency, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Dong Wan" sort="Kim, Dong Wan" uniqKey="Kim D" first="Dong-Wan" last="Kim">Dong-Wan Kim</name><affiliation wicri:level="3"><nlm:affiliation>Seoul National University Hospital, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Seoul National University Hospital, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Arvis, Catherine Dubos" sort="Arvis, Catherine Dubos" uniqKey="Arvis C" first="Catherine Dubos" last="Arvis">Catherine Dubos Arvis</name><affiliation wicri:level="3"><nlm:affiliation>Centre François Baclesse, Oncology, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre François Baclesse, Oncology, Caen</wicri:regionArea><placeName><region type="region">Région Normandie</region><region type="old region">Basse-Normandie</region><settlement type="city">Caen</settlement></placeName></affiliation></author><author><name sortKey="Kolbeck, Karl" sort="Kolbeck, Karl" uniqKey="Kolbeck K" first="Karl" last="Kölbeck">Karl Kölbeck</name><affiliation wicri:level="3"><nlm:affiliation>Karolinska University Hospital, Solna, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska University Hospital, Solna, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Laurie, Scott A" sort="Laurie, Scott A" uniqKey="Laurie S" first="Scott A" last="Laurie">Scott A. Laurie</name><affiliation wicri:level="1"><nlm:affiliation>The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Ottawa Hospital Cancer Centre, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name><affiliation wicri:level="1"><nlm:affiliation>Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Taipei Veterans General Hospital and National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Shahidi, Mehdi" sort="Shahidi, Mehdi" uniqKey="Shahidi M" first="Mehdi" last="Shahidi">Mehdi Shahidi</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Miyoung" sort="Kim, Miyoung" uniqKey="Kim M" first="Miyoung" last="Kim">Miyoung Kim</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim GmbH, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim GmbH, Ingelheim</wicri:regionArea><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion></affiliation></author><author><name sortKey="Massey, Dan" sort="Massey, Dan" uniqKey="Massey D" first="Dan" last="Massey">Dan Massey</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Paz Ares, Luis" sort="Paz Ares, Luis" uniqKey="Paz Ares L" first="Luis" last="Paz-Ares">Luis Paz-Ares</name><affiliation><nlm:affiliation>Hospital Universitario Doce de Octubre and CNIO, Madrid Spain.</nlm:affiliation><wicri:noCountry code="subField">Madrid Spain</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27083334</idno><idno type="pmid">27083334</idno><idno type="doi">10.1016/S1470-2045(16)30033-X</idno><idno type="wicri:Area/PubMed/Corpus">001E66</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E66</idno><idno type="wicri:Area/PubMed/Curation">001E42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E42</idno><idno type="wicri:Area/PubMed/Checkpoint">001E42</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E42</idno><idno type="wicri:Area/Ncbi/Merge">003419</idno><idno type="wicri:Area/Ncbi/Curation">003419</idno><idno type="wicri:Area/Ncbi/Checkpoint">003419</idno><idno type="wicri:Area/Main/Merge">002398</idno><idno type="wicri:Area/Main/Curation">002399</idno><idno type="wicri:Area/Main/Exploration">002399</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.</title><author><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name><affiliation wicri:level="3"><nlm:affiliation>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: kpark@skku.edu.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Tan, Eng Huat" sort="Tan, Eng Huat" uniqKey="Tan E" first="Eng-Huat" last="Tan">Eng-Huat Tan</name><affiliation wicri:level="1"><nlm:affiliation>National Cancer Centre, Singapore, Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>National Cancer Centre, Singapore</wicri:regionArea><wicri:noRegion>Singapore</wicri:noRegion></affiliation></author><author><name sortKey="O Byrne, Ken" sort="O Byrne, Ken" uniqKey="O Byrne K" first="Ken" last="O'Byrne">Ken O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou</wicri:regionArea><placeName><settlement type="city">Jiangmen</settlement><region type="province">Guangdong</region></placeName></affiliation></author><author><name sortKey="Boyer, Michael" sort="Boyer, Michael" uniqKey="Boyer M" first="Michael" last="Boyer">Michael Boyer</name><affiliation wicri:level="1"><nlm:affiliation>Chris O'Brien Lifehouse, Camperdown, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Chris O'Brien Lifehouse, Camperdown, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong Sha Tin, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong Sha Tin</wicri:regionArea><wicri:noRegion>The Chinese University of Hong Kong Sha Tin</wicri:noRegion></affiliation></author><author><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name><affiliation wicri:level="4"><nlm:affiliation>McGill University, Montreal, QC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>McGill University, Montreal, QC</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Yang, James Chih Hsin" sort="Yang, James Chih Hsin" uniqKey="Yang J" first="James Chih-Hsin" last="Yang">James Chih-Hsin Yang</name><affiliation wicri:level="1"><nlm:affiliation>National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Ki Hyeong" sort="Lee, Ki Hyeong" uniqKey="Lee K" first="Ki Hyeong" last="Lee">Ki Hyeong Lee</name><affiliation wicri:level="1"><nlm:affiliation>Chungbuk National University Hospital, Cheongju, Chungbuk, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Chungbuk National University Hospital, Cheongju, Chungbuk</wicri:regionArea><wicri:noRegion>Chungbuk</wicri:noRegion></affiliation></author><author><name sortKey="Lu, Shun" sort="Lu, Shun" uniqKey="Lu S" first="Shun" last="Lu">Shun Lu</name><affiliation wicri:level="1"><nlm:affiliation>Shanghai Chest Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Shanghai Chest Hospital, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Shi, Yuankai" sort="Shi, Yuankai" uniqKey="Shi Y" first="Yuankai" last="Shi">Yuankai Shi</name><affiliation wicri:level="3"><nlm:affiliation>Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Kim, Sang We" sort="Kim, Sang We" uniqKey="Kim S" first="Sang-We" last="Kim">Sang-We Kim</name><affiliation wicri:level="3"><nlm:affiliation>Asan Medical Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Asan Medical Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Laskin, Janessa" sort="Laskin, Janessa" uniqKey="Laskin J" first="Janessa" last="Laskin">Janessa Laskin</name><affiliation wicri:level="1"><nlm:affiliation>BC CancerAgency, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>BC CancerAgency, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Dong Wan" sort="Kim, Dong Wan" uniqKey="Kim D" first="Dong-Wan" last="Kim">Dong-Wan Kim</name><affiliation wicri:level="3"><nlm:affiliation>Seoul National University Hospital, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Seoul National University Hospital, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Arvis, Catherine Dubos" sort="Arvis, Catherine Dubos" uniqKey="Arvis C" first="Catherine Dubos" last="Arvis">Catherine Dubos Arvis</name><affiliation wicri:level="3"><nlm:affiliation>Centre François Baclesse, Oncology, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre François Baclesse, Oncology, Caen</wicri:regionArea><placeName><region type="region">Région Normandie</region><region type="old region">Basse-Normandie</region><settlement type="city">Caen</settlement></placeName></affiliation></author><author><name sortKey="Kolbeck, Karl" sort="Kolbeck, Karl" uniqKey="Kolbeck K" first="Karl" last="Kölbeck">Karl Kölbeck</name><affiliation wicri:level="3"><nlm:affiliation>Karolinska University Hospital, Solna, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Karolinska University Hospital, Solna, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Laurie, Scott A" sort="Laurie, Scott A" uniqKey="Laurie S" first="Scott A" last="Laurie">Scott A. Laurie</name><affiliation wicri:level="1"><nlm:affiliation>The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Ottawa Hospital Cancer Centre, Ottawa, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name><affiliation wicri:level="1"><nlm:affiliation>Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Taipei Veterans General Hospital and National Yang-Ming University, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="Shahidi, Mehdi" sort="Shahidi, Mehdi" uniqKey="Shahidi M" first="Mehdi" last="Shahidi">Mehdi Shahidi</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Miyoung" sort="Kim, Miyoung" uniqKey="Kim M" first="Miyoung" last="Kim">Miyoung Kim</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim GmbH, Ingelheim, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Boehringer Ingelheim GmbH, Ingelheim</wicri:regionArea><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion><wicri:noRegion>Ingelheim</wicri:noRegion></affiliation></author><author><name sortKey="Massey, Dan" sort="Massey, Dan" uniqKey="Massey D" first="Dan" last="Massey">Dan Massey</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name><affiliation wicri:level="1"><nlm:affiliation>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Boehringer Ingelheim Ltd UK, Bracknell, Berkshire</wicri:regionArea><wicri:noRegion>Berkshire</wicri:noRegion></affiliation></author><author><name sortKey="Paz Ares, Luis" sort="Paz Ares, Luis" uniqKey="Paz Ares L" first="Luis" last="Paz-Ares">Luis Paz-Ares</name><affiliation><nlm:affiliation>Hospital Universitario Doce de Octubre and CNIO, Madrid Spain.</nlm:affiliation><wicri:noCountry code="subField">Madrid Spain</wicri:noCountry></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Carcinoma, Non-Small-Cell Lung (genetics)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Disease-Free Survival</term><term>Drug-Related Side Effects and Adverse Reactions (classification)</term><term>Drug-Related Side Effects and Adverse Reactions (genetics)</term><term>Drug-Related Side Effects and Adverse Reactions (physiopathology)</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Mutation</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Quinazolines (administration & dosage)</term><term>Quinazolines (adverse effects)</term><term>Receptor, Epidermal Growth Factor (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (génétique)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Effets secondaires indésirables des médicaments ()</term><term>Effets secondaires indésirables des médicaments (génétique)</term><term>Effets secondaires indésirables des médicaments (physiopathologie)</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (administration et posologie)</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Mutation</term><term>Mâle</term><term>Quinazolines (administration et posologie)</term><term>Quinazolines (effets indésirables)</term><term>Récepteur du facteur de croissance épidermique (génétique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Quinazolines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Drug-Related Side Effects and Adverse Reactions</term><term>Receptor, Epidermal Growth Factor</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Effets secondaires indésirables des médicaments</term><term>Récepteur du facteur de croissance épidermique</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Mutation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Effets secondaires indésirables des médicaments</term><term>Estimation de Kaplan-Meier</term><term>Femelle</term><term>Humains</term><term>Mutation</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Corée du Sud</li><li>France</li><li>Hong Kong</li><li>Royaume-Uni</li><li>République populaire de Chine</li><li>Singapour</li><li>Suède</li><li>Taïwan</li></country><region><li>Basse-Normandie</li><li>Guangdong</li><li>Québec</li><li>Région Normandie</li><li>Région capitale de Séoul</li><li>Svealand</li></region><settlement><li>Caen</li><li>Jiangmen</li><li>Montréal</li><li>Pékin</li><li>Stockholm</li><li>Séoul</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><noCountry><name sortKey="Paz Ares, Luis" sort="Paz Ares, Luis" uniqKey="Paz Ares L" first="Luis" last="Paz-Ares">Luis Paz-Ares</name></noCountry><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Park, Keunchil" sort="Park, Keunchil" uniqKey="Park K" first="Keunchil" last="Park">Keunchil Park</name></region><name sortKey="Kim, Dong Wan" sort="Kim, Dong Wan" uniqKey="Kim D" first="Dong-Wan" last="Kim">Dong-Wan Kim</name><name sortKey="Kim, Sang We" sort="Kim, Sang We" uniqKey="Kim S" first="Sang-We" last="Kim">Sang-We Kim</name><name sortKey="Lee, Ki Hyeong" sort="Lee, Ki Hyeong" uniqKey="Lee K" first="Ki Hyeong" last="Lee">Ki Hyeong Lee</name></country><country name="Singapour"><noRegion><name sortKey="Tan, Eng Huat" sort="Tan, Eng Huat" uniqKey="Tan E" first="Eng-Huat" last="Tan">Eng-Huat Tan</name></noRegion></country><country name="Australie"><noRegion><name sortKey="O Byrne, Ken" sort="O Byrne, Ken" uniqKey="O Byrne K" first="Ken" last="O'Byrne">Ken O'Byrne</name></noRegion><name sortKey="Boyer, Michael" sort="Boyer, Michael" uniqKey="Boyer M" first="Michael" last="Boyer">Michael Boyer</name></country><country name="République populaire de Chine"><region name="Guangdong"><name sortKey="Zhang, Li" sort="Zhang, Li" uniqKey="Zhang L" first="Li" last="Zhang">Li Zhang</name></region><name sortKey="Lu, Shun" sort="Lu, Shun" uniqKey="Lu S" first="Shun" last="Lu">Shun Lu</name><name sortKey="Shi, Yuankai" sort="Shi, Yuankai" uniqKey="Shi Y" first="Yuankai" last="Shi">Yuankai Shi</name></country><country name="Hong Kong"><noRegion><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name></noRegion></country><country name="Canada"><region name="Québec"><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name></region><name sortKey="Laskin, Janessa" sort="Laskin, Janessa" uniqKey="Laskin J" first="Janessa" last="Laskin">Janessa Laskin</name><name sortKey="Laurie, Scott A" sort="Laurie, Scott A" uniqKey="Laurie S" first="Scott A" last="Laurie">Scott A. Laurie</name></country><country name="Taïwan"><noRegion><name sortKey="Yang, James Chih Hsin" sort="Yang, James Chih Hsin" uniqKey="Yang J" first="James Chih-Hsin" last="Yang">James Chih-Hsin Yang</name></noRegion><name sortKey="Tsai, Chun Ming" sort="Tsai, Chun Ming" uniqKey="Tsai C" first="Chun-Ming" last="Tsai">Chun-Ming Tsai</name></country><country name="France"><region name="Région Normandie"><name sortKey="Arvis, Catherine Dubos" sort="Arvis, Catherine Dubos" uniqKey="Arvis C" first="Catherine Dubos" last="Arvis">Catherine Dubos Arvis</name></region></country><country name="Suède"><region name="Svealand"><name sortKey="Kolbeck, Karl" sort="Kolbeck, Karl" uniqKey="Kolbeck K" first="Karl" last="Kölbeck">Karl Kölbeck</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Shahidi, Mehdi" sort="Shahidi, Mehdi" uniqKey="Shahidi M" first="Mehdi" last="Shahidi">Mehdi Shahidi</name></noRegion><name sortKey="Massey, Dan" sort="Massey, Dan" uniqKey="Massey D" first="Dan" last="Massey">Dan Massey</name><name sortKey="Zazulina, Victoria" sort="Zazulina, Victoria" uniqKey="Zazulina V" first="Victoria" last="Zazulina">Victoria Zazulina</name></country><country name="Allemagne"><noRegion><name sortKey="Kim, Miyoung" sort="Kim, Miyoung" uniqKey="Kim M" first="Miyoung" last="Kim">Miyoung Kim</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002399 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002399 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27083334
|texte= Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27083334" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |